✦ LIBER ✦

Phase I / II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer

✍ Scribed by G. T. Budd; J. Atiba; R. T. Silver; G. Palmer; S. Armstrong; K. Otto; C. Presant

Publisher: Springer-Verlag
Year: 1999
Tongue: English
Weight: 96 KB
Volume: 125
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s004320050308

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of paclitaxel, carboplatin

Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer

✍ John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 3 views

## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that

Erythropoietin and granulocyte-macrophag

Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer

✍ M. Venturini; L. Del Mastro; Franco Testore; Marco Danova; Ornella Garrone; Clau 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 160 KB

Phase II study of cisplatin as a 5-day c

Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer

✍ Yoshikuni Saito; Kiyoshi Mori; Keigo Tominaga; Kouhei Yokoi; Naoto Miyazawa 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 500 KB

A phase-I trial of the epidermal growth

A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors

✍ Matthew G. Fury; Allan Lipton; Katherine M. Smith; Corinne B. Winston; David G. 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 377 KB

A phase I trial to assess the value of r

A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (r-MetHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL)

✍ G. M. Smith; J. A. Child; M. H. Cullen; N. P. Bailey; C. M. Woodruffe; J. Fletch 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

In a multi-centre phase I study we investigated the possibility of reducing the interval between courses of standard CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m', vincristine 2 mgs day 1, and prednisolone 40mglm' days 1-8) from 21 days to 15 days and then 10 days using granulocyte colony s

Phase II study of intensive chemotherapy

Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer

✍ Giorgio Vittorio Scagliotti; Umberto Ricardi; Lucio Crinó; Ernesto Maranzano; Fi 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 375 KB